Factors affecting cognitive remediation response in schizophrenia: The role of COMT gene and antipsychotic treatment

Psychiatry Research

Volumn 217, Issue 1-2, 2014, Pages 9-14

  Bosia, Marta ^a,b   Zanoletti, Andrea ^c   Spangaro, Marco ^a,c   Buonocore, Mariachiara ^a   Bechi, Margherita ^a   Cocchi, Federica ^a   Pirovano, Adele ^c   Lorenzi, Cristina ^a   Bramanti, Placido ^d   Smeraldi, Enrico ^a,c   Cavallaro, Roberto ^a  

^a SAN RAFFAELE HOSPITAL   (Italy)

^b SCUOLA UNIVERSITARIA SUPERIORE IUSS PAVIA   (Italy)

^c VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^d IRCCS CENTRO NEUROLESI BONINO PULEJO   (Italy)

Author keywords

Catechol O methyltransferase; Clozapine; Cognitive remediation; Genetics; Schizophrenia

Indexed keywords

CATECHOL METHYLTRANSFERASE; CLOZAPINE; DOPAMINE; NEUROLEPTIC AGENT;

ADULT; AGED; ARTICLE; COGNITIVE REHABILITATION; COGNITIVE REMEDIATION THERAPY; COMT GENE; CONTROLLED STUDY; FEMALE; GENE FREQUENCY; GENE FUNCTION; GENE INTERACTION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HUMAN; MAJOR CLINICAL STUDY; MALE; MOTOR COORDINATION; PRIORITY JOURNAL; PSYCHOMOTOR PERFORMANCE; SCHIZOPHRENIA; SPEECH ARTICULATION; TREATMENT RESPONSE; VERBAL MEMORY; WORKING MEMORY; ADOLESCENT; COGNITION; COGNITIVE THERAPY; ENZYMOLOGY; GENETICS; GENOTYPE; METABOLISM; MIDDLE AGED; PATHOPHYSIOLOGY; PHYSIOLOGY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTIPSYCHOTIC AGENTS; CATECHOL O-METHYLTRANSFERASE; CLOZAPINE; COGNITION; COGNITIVE THERAPY; DOPAMINE; FEMALE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; SCHIZOPHRENIA; YOUNG ADULT;

EID: 84899918658     PISSN: 01651781     EISSN: 18727123     Source Type: Journal    
DOI: 10.1016/j.psychres.2014.02.015     Document Type: Article

References (49)

1. Angelucci F., Mathé A.A., Aloe L. Brain-derived neurotrophic factor and tyrosine kinase receptor TrkB in rat brain are significantly altered after haloperidol and risperidone administration. Journal of Neuroscience Research 2000, 60(6):783-794.
2. Bai O., Chlan-Fourney J., Bowen R., Keegan D., Li X.M. Expression of brain-derived neurotrophic factor mRNA in rat hippocampus after treatment with antipsychotic drugs. Journal of Neuroscience Research 2003, 71(1):127-131.
3. Bertolino A., Caforio G., Blasi G., De Candia M., Latorre V., Petruzzella V., Altamura M., Nappi G., Papa S., Callicott J.H., Mattay V.S., Bellomo A., Scarabino T., Weimberger D.R., Nardini M. Interaction of COMT (Val(108/158)Met) genotype and olanzapine treatment on prefrontal cortical function in patients with schizophrenia. American Journal of Psychiatry 2004, 161:1798-1805.
4. Bertolino A., Caforio G., Petruzzella V., Latorre V., Rubino V., Dimalta S., Torraco A., Blasi G., Quartesan R., Mattay V.S., Callicott J.H., Weinberger D.R., Scarabino T. Prefrontal dysfunction in schizophrenia controlling for COMT Val158Met genotype and working memory performance. Psychiatry Research 2006, 147(2-3):221-226.
5. Bor J., Brunelin J., d[U+05F3]Amato T., Costes N., Suaud-Chagny M.F., Saoud M., Poulet E. How can cognitive remediation therapy modulate brain activations in schizophrenia? An fMRI study. Psychiatry Research 2011, 192(3):160-166.
6. Bosia M., Bechi M., Marino E., Anselmetti S., Poletti S., Cocchi F., Smeraldi E., Cavallaro R. Influence of catechol-O-methyltransferase Val158Met polymorphism on neuropsychological and functional outcomes of classical rehabilitation and cognitive remediation in schizophrenia. Neuroscience Letters 2007, 417(3):271-274.
7. Brenner H.D., Roder V., Hodel B., Kienzle N., Reed D., Liberman R.P. Integrated Psychological Therapy for Schizophrenic Patients 1994, Hogrefe & Huber, Seattle, WA.
8. Chou Y.H., Halldin C., Farde L. Clozapine binds preferentially to cortical D1-like dopamine receptors in the primate brain: a PET study. Psychopharmacology 2006, 185(1):29-35.
9. Diaz-Asper C.M., Goldberg T.E., Kolachana B.S., Straub R.E., Egan M.F., Weinberger D.R. Genetic variation in catechol-O-methyltransferase: effects on working memory in schizophrenic patients, their siblings, and healthy controls. Biological Psychiatry 2008, 63(1):72-79.
10. Dickinson D., Ramsey M.E., Gold J.M. Overlooking the obvious: a meta-analytic comparison of digit symbol coding tasks and other cognitive measures in schizophrenia. Archives of General Psychiatry 2007, 64(5):532-542.
11. Egan M.F., Goldberg T.E., Kolachana B.S., Callicott J.H., Mazzanti C.M., Straub R.E., Goldman D., Weinberger D.R. Effect of COMT Val108/158 Met genotype on frontal lobe function and risk for schizophrenia. Proceedings of the National Academy of Science of the United States of America 2001, 98(12):6917-6922.
12. Ehlis A.C., Herrmann M.J., Pauli P., Stoeber G., Pfuhlmann B., Fallgatter A.J. Improvement of prefrontal brain function in endogenous psychoses under atypical antipsychotic treatment. Neuropsychopharmacology 2007, 32(8):1669-1677.
13. Faron-Górecka A., Górecki A., Kuśmider M., Wasylewski Z., Dziedzicka-Wasylewska M. The role of D1-D2 receptor hetero-dimerization in the mechanism of action of clozapine. European Neuropsychopharmacology 2008, 18(9):682-691.
14. Goldberg T.E., Egan M.F., Gscheidle T., Coppola R., Weickert T., Kolachana B.S., Goldman D., Weinberger D.R. Executive sub- processes in working memory: relationship to catechol-O-methyltransferase Val158Met genotype and schizophrenia. Archives of General Psychiatry 2003, 60:889-896.
15. Green A.E., Kraemer D.J., Deyoung C.G., Fossella J.A., Gray J.R. A gene-brain-cognition pathway: prefrontal activity mediates the effect of COMT on cognitive control and IQ. Cerebral Cortex 2013, 23(3):552-559.
16. Greenwood K., Hung C.F., Tropeano M., McGuffin P., Wykes T. No association between the Catechol-O-Methyltransferase (COMT) val158met polymorphism and cognitive improvement following cognitive remediation therapy (CRT) in schizophrenia. Neuroscience Letters 2011, 496(2):65-69.
17. Harvey P.D., Keefe R.S.E. Studies of cognitive changes in patients with schizophrenia following novel antipsychotic treatment. American Journal of Psychiatry 2001, 158:176-184.
18. Haut K.M., Lim K.O., MacDonald A. Prefrontal cortical changes following cognitive training in patients with chronic schizophrenia: effects of practice, generalization, and specificity. Neuropsychopharmacology 2010, 35(9):1850-1859.
19. Kay S.R., Fiszbein A., Opler L.A. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophrenia Bulletin 1987, 13(2):261-276.
20. Keefe R.S., Goldberg T.E., Harvey P.D., Gold J.M., Poe M.P., Coughenour L. The Brief Assessment of Cognition in Schizophrenia: reliability, sensitivity, and comparison with a standard neurocognitive battery. Schizophrenia Research 2004, 68(2-3):283-297.
21. Keefe R.S., Seidman L.J., Christensen B.K., Hamer R.M., Sharma T., Sitskoorn M.M., Lewine R.R., Yurgelun-Todd D.A., Gur R.C., Tohen M., Tollefson G.D., Sanger T.M., Lieberman J.A. Comparative effect of atypical and conventional antipsychotic drugs on neurocognition in first-episode psychosis: a randomized, double-blind trial of olanzapine versus low doses of haloperidol. American Journal of Psychiatry 2004, 161(6):985-995.
22. Keefe R.S., Bilder R.M., Davis S.M., Harvey P.D., Palmer B.W., Gold J.M., Meltzer H.Y., Green M.F., Capuano G., Stroup T.S., McEvoy J.P., Swartz M.S., Rosenheck R.A., Perkins D.O., Davis C.E., Hsiao J.K., Lieberman J.A. Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial. Archives of General Psychiatry 2007, 64(6):633-647.
23. Keefe R.S., Harvey P.D. Cognitive impairment in schizophrenia. Handbook of Experimental Pharmacology, Springer 2012, 213:11-37.
24. Kucharska-Pietura K., Mortimer A., Tylec A., Czernikiewicz A. Social cognition and visual perception in schizophrenia inpatients treated with first-and second-generation antipsychotic drugs. Clinical Schizophrenia & Related Psychoses 2012, 6(1):14-20.
25. Lin CH., Wang F.C., Lin S,C, Huang Y.H., Chen C.C., Lane H.Y. Antipsychotic combination using low-dose antipsychotics is as efficacious and safe as, but cheaper, than optimal-dose monotherapy in the treatment of schizophrenia: a randomized, double-blind study. Journal of Clinical Psychopharmacology 2013, 28(5):267-274.
26. McNab F., Varrone A., Farde L., Jucaite A., Bystritsky P., Forssberg H., Klingberg T. Changes in cortical dopamine D1 receptor binding associated with cognitive training. Science 2009, 323(5915):800-802.
27. Medalia A., Choi J. Cognitive remediation in schizophrenia. Neuropsychology Review 2009, 19(3):353-364.
28. Meltzer H.Y., Massey B.W. The role of serotonin receptors in the action of atypical antipsychotic drugs. Current Opinion in Pharmacology 2011, 11(1):59-67.
29. Molina V., Tamayo P., Montes C., De Luxán A., Martin C., Rivas N., Sancho C., Domínguez-Gil A. Clozapine may partially compensate for task-related brain perfusion abnormalities in risperidone-resistant schizophrenia patients. Progress in Neuro-Psychopharmacology and Biological Psychiatry 2008, 32(4):948-954.
30. Panizzutti R., Hamilton S.P., Vinogradov S. Genetic correlate of cognitive training response in schizophrenia. Neuropharmacology 2013, 64:264-267.
31. Pedrini M., Chendo I., Grande I., Lobato M.I., Belmonte-de-Abreu P.S., Lersch C., Walz J., Kauer-Sant[U+05F3]anna M., Kapczinski F., Gama C.S. Serum brain-derived neurotrophic factor and clozapine daily dose in patients with schizophrenia: a positive correlation. Neuroscience Letters 2011, 491(3):207-210.
32. Penadés R., Pujol N., Catalán R., Massana G., Rametti G., García-Rizo C., Bargalló N., Gastó C., Bernardo M., Junqué C. Brain effects of cognitive remediation therapy in schizophrenia: a structural and functional neuroimaging study. Biological Psychiatry 2013, (Epub ahead of print).
33. Pieramico V., Esposito R., Sensi F., Cilli F., Mantini D., Mattei P.A. Combination training in aging individuals modifies functional connectivity and cognition, and is potentially affected by dopamine-related genes. PLoS One 2012, 7(8):e43901.
34. Plewnia C., Zwissler B., Längst I., Maurer B., Giel K., Krüger R. Effects of transcranial direct current stimulation (tDCS) on executive functions: Influence of COMT Val/Met polymorphism. Cortex 2012, (Epub ahead of print).
35. Purkayastha S., Ford J., Kanjilal B., Diallo S., Del Rosario Inigo J., Neuwirth L., El Idrissi A., Ahmed Z., Wieraszko A., Azmitia E.C., Banerjee P. Clozapine functions through the prefrontal cortex serotonin 1A receptor to heighten neuronal activity via calmodulin kinase II-NMDA receptor interactions. Journal of Neurochemistry 2012, 120(3):396-407.
36. Rémillard S., Pourcher E., Cohen H. Long-term effects of risperidone versus haloperidol on verbal memory, attention, and symptomatology in schizophrenia. Journal of the International Neuropsychological Society 2008, 14(1):110-118.
37. Rosa A., Peralta V., Cuesta M.J., Zarzuela A., Serrano F., Martinez-Larrea A., Fananas L. New evidence of association between COMT gene and prefrontal neurocognitive function in healthy individuals from sibling pairs discordant for psychosis. American Journal of Psychiatry 2004, 161:1110-1112.
38. Slifstein M., Kolachana B., Simpson E.H., Tabares P., Cheng B., Duvall M., Frankle W.G., Weinberger D.R., Laruelle M., Abi-Dargham A. COMT genotype predicts cortical-limbic D1 receptor availability measured with [11C]NNC112 and PET. Molecular Psychiatry 2008, 13(8):821-827.
39. Stroth S., Reinhardt R.K., Thöne J., Hille K., Schneider M., Härtel S., Weidemann W., Bös K., Spitzer M. Source Impact of aerobic exercise training on cognitive functions and affect associated to the COMT polymorphism in young adults. Neurobiology of Learning and Memory 2010, 94(3):364-372.
40. Tauscher J., Hussain T., Agid O., Verhoeff N.P., Wilson A.A., Houle S., Remington G., Zipursky R.B., Kapur S. Equivalent occupancy of dopamine D1 and D2 receptors with clozapine: differentiation from other atypical antipsychotics. American Journal of Psychiatry 2004, 161(9):1620-1625.
41. Wechsler D. Wechsler Adult Intelligence Scale-Revised (WAIS-R) 2006, Psychological Corporation, San Antonio, TX.
42. Weickert T.W., Goldberg T.E., Mishara A., Apud J.A., Kolachana B.S., Egan M.F., Weinberger D.R. Catechol-O-methyltransferase val108/158met genotype predicts working memory response to antipsychotic medications. Biological Psychiatry 2004, 56(9):677-682.
43. Winterer G., Goldman D. Genetics of human prefrontal function. Brain Research Reviews 2003, 43(1):134-163.
44. Witte A.V., Kürten J., Jansen S., Schirmacher A., Brand E., Sommer J., Flöel A. Interaction of BDNF and COMT polymorphisms on paired-associative stimulation-induced cortical plasticity. Journal of Neuroscience 2012, 32(13):4553-4561.
45. Woodward N.D., Jayathilake K., Meltzer H.Y. COMT val108/158met genotype, cognitive function, and cognitive improvement with clozapine in schizophrenia. Schizophrenia Research 2007, 90(1-3):86-96.
46. Wykes T., Reeder C., Corner J., Williams C., Everitt B. The effects of neurocognitive remediation on executive processing in patients with schizophrenia. Schizophrenia Bulletin 1999, 25:291-307.
47. Wykes T., Brammer M., Mellers J., Bray P., Reeder C., Williams C., Corner J. Effects on the brain of a psychological treatment: cognitive remediation therapy: functional magnetic resonance imaging in schizophrenia. British Journal of Psychiatry 2002, 181:144-152.
48. Wykes T., Huddy V., Cellard C., McGurk S.R., Czobor P. A meta-analysis of cognitive remediation for schizophrenia: methodology and effect sizes. American Journal of Psychiatry 2011, 168(5):472-485.
49. Wykes T., Spaulding W.D. Thinking about the future cognitive remediation therapy-what works and could we do better?. Schizophrenia Bulletin 2011, 37(Suppl. 2):S80-S90.